Neurological and Psychological Sequelae Associated With Multisystem Inflammatory Syndrome in Children
dc.contributor.author | Rollins, Caitlin K. | |
dc.contributor.author | Calderon, Johanna | |
dc.contributor.author | Wypij, David | |
dc.contributor.author | Taylor, Alex M. | |
dc.contributor.author | Kanjiker, Tahera Sultana Davalji | |
dc.contributor.author | Rohde, Julia S. | |
dc.contributor.author | Maiman, Moshe | |
dc.contributor.author | Zambrano, Laura D. | |
dc.contributor.author | Newhams, Margaret M. | |
dc.contributor.author | Rodriguez, Susan | |
dc.contributor.author | Hart, Nicholas | |
dc.contributor.author | Worhach, Jennifer | |
dc.contributor.author | Kucukak, Suden | |
dc.contributor.author | Poussaint, Tina Y. | |
dc.contributor.author | Son, Mary Beth F. | |
dc.contributor.author | Friedman, Matthew L. | |
dc.contributor.author | Gertz, Shira J. | |
dc.contributor.author | Hobbs, Charlotte V. | |
dc.contributor.author | Kong, Michele | |
dc.contributor.author | Maddux, Aline B. | |
dc.contributor.author | McGuire, Jennifer L. | |
dc.contributor.author | Licht, Paul A. | |
dc.contributor.author | Allen Staat, Mary | |
dc.contributor.author | Yonker, Lael M. | |
dc.contributor.author | Mazumdar, Maitreyi | |
dc.contributor.author | Randolph, Adrienne G. | |
dc.contributor.author | Campbell, Angela P. | |
dc.contributor.author | Newburger, Jane W. | |
dc.contributor.author | Overcoming COVID-19 Investigators | |
dc.contributor.department | Pediatrics, School of Medicine | |
dc.date.accessioned | 2024-02-13T18:55:30Z | |
dc.date.available | 2024-02-13T18:55:30Z | |
dc.date.issued | 2023-07-03 | |
dc.description.abstract | Importance: Acute neurological involvement occurs in some patients with multisystem inflammatory syndrome in children (MIS-C), but few data report neurological and psychological sequelae, and no investigations include direct assessments of cognitive function 6 to 12 months after discharge. Objective: To characterize neurological, psychological, and quality of life sequelae after MIS-C. Design, setting, and participants: This cross-sectional cohort study was conducted in the US and Canada. Participants included children with MIS-C diagnosed from November 2020 through November 2021, 6 to 12 months after hospital discharge, and their sibling or community controls, when available. Data analysis was performed from August 2022 to May 2023. Exposure: Diagnosis of MIS-C. Main outcomes and measures: A central study site remotely administered a onetime neurological examination and in-depth neuropsychological assessment including measures of cognition, behavior, quality of life, and daily function. Generalized estimating equations, accounting for matching, assessed for group differences. Results: Sixty-four patients with MIS-C (mean [SD] age, 11.5 [3.9] years; 20 girls [31%]) and 44 control participants (mean [SD] age, 12.6 [3.7] years; 20 girls [45%]) were enrolled. The MIS-C group exhibited abnormalities on neurological examination more frequently than controls (15 of 61 children [25%] vs 3 of 43 children [7%]; odds ratio, 4.7; 95% CI, 1.3-16.7). Although the 2 groups performed similarly on most cognitive measures, the MIS-C group scored lower on the National Institutes of Health Cognition Toolbox List Sort Working Memory Test, a measure of executive functioning (mean [SD] scores, 96.1 [14.3] vs 103.1 [10.5]). Parents reported worse psychological outcomes in cases compared with controls, particularly higher scores for depression symptoms (mean [SD] scores, 52.6 [13.1] vs 47.8 [9.4]) and somatization (mean [SD] scores, 55.5 [15.5] vs 47.0 [7.6]). Self-reported (mean [SD] scores, 79.6 [13.1] vs 85.5 [12.3]) and parent-reported (mean [SD] scores, 80.3 [15.5] vs 88.6 [13.0]) quality of life scores were also lower in cases than controls. Conclusions and relevance: In this cohort study, compared with contemporaneous sibling or community controls, patients with MIS-C had more abnormal neurologic examinations, worse working memory scores, more somatization and depression symptoms, and lower quality of life 6 to 12 months after hospital discharge. Although these findings need to be confirmed in larger studies, enhanced monitoring may be warranted for early identification and treatment of neurological and psychological symptoms. | |
dc.identifier.citation | Rollins CK, Calderon J, Wypij D, et al. Neurological and Psychological Sequelae Associated With Multisystem Inflammatory Syndrome in Children. JAMA Netw Open. 2023;6(7):e2324369. Published 2023 Jul 3. doi:10.1001/jamanetworkopen.2023.24369 | |
dc.identifier.uri | https://hdl.handle.net/1805/38456 | |
dc.language.iso | en_US | |
dc.publisher | American Medical Association | |
dc.relation.isversionof | 10.1001/jamanetworkopen.2023.24369 | |
dc.relation.journal | JAMA Network Open | |
dc.rights | Attribution 4.0 International | en |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.source | PMC | |
dc.subject | Connective tissue diseases | |
dc.subject | Quality of life | |
dc.subject | Systemic inflammatory response syndrome | |
dc.subject | Disease progression | |
dc.title | Neurological and Psychological Sequelae Associated With Multisystem Inflammatory Syndrome in Children | |
dc.type | Article |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Neurological and Psychological Sequelae Associated With Multisystem Inflammator.pdf
- Size:
- 1.63 MB
- Format:
- Adobe Portable Document Format
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.99 KB
- Format:
- Item-specific license agreed upon to submission
- Description: